Abstract

ABSTRACT There has been growing interest of using machine learning (ML) methods with real-world data (RWD) to generate real-world evidence (RWE) to support regulatory decisions. In the U.S. Food and Drug Administration (FDA), ML has been applied in both prediction and causal inference problems for drug safety evaluation. The ML applications include health outcome identification, missing data imputation, risk factor identification, drug utilization discovery and causal inference study. We demonstrate the present utility and future potential of ML for regulatory science. We then discuss the challenges and considerations when using ML methods with RWD to generate RWE. Specifically, we focus on the transparency and reproducibility issue of using ML, the potential of ML and natural language processing (NLP) for missing data in RWD, training data issue for rare events, and interpretability of studies using ML.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.